Skip to main content
Equibles
TLPH logo

TLPH · Talphera, Inc.

Track TLPH — free

Use TLPH with AI

Ask our own analyst here, or connect this data to the AI you already use.

Ask ALVIS about TLPH

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

or use your own AI

The free Equibles MCP server lets any client query SEC filings, earnings calls, KPIs, holdings and prices directly — read-only, OAuth-secured, cited to the filing.

ChatGPT Claude Gemini
Server URL
https://mcp.equibles.com/mcp
All connection guides →
$1.23 +0.02 (+1.65%) At close · Aug 14
Going-concern doubt — flagged Aug 12, 2026

Substantial doubt about the company's ability to continue as a going concern.

“These conditions raise substantial doubt about the Company's ability to continue as a going concern. While management believes its plans to raise additional funds will alleviate the conditions that raise substantial doubt about the Company's ability to continue as a going concern, these plans are not entirely within the Company's control and cannot be assessed as being probable of occurring.”
View the 10-Q filed Aug 12, 2026
Market Cap
$63.84M
Shares
51.91M

Talphera, Inc. Earnings Call Transcripts

Every quarterly earnings call for Talphera, Inc. (TLPH) — the full transcript with speaker labels, the audio replay, AI call highlights and a management-tone score, plus the matching 8-K earnings release and the quarter's 10-Q or 10-K. Investor days and conferences appear here too.

Revenue & result across quarters

Revenue Net income YoY up YoY down artefacts
▼100% $ −$6.75M '22 Q3 22-11-14 ▼22200% $ −$7.48M '22 Q4 23-03-30 · $253,000 −$4.37M '23 Q2 23-08-10 · $117,000 −$1.36M '23 Q3 23-11-08 · $ −$3.95M '24 Q1 24-05-14 ▼100% $ −$3.83M '24 Q2 24-08-14 ▼100% $ −$3.35M '24 Q3 24-11-13 · $ −$1.87M '24 Q4 25-03-31 · $27,000 −$2.59M '25 Q1 25-05-14 · $ −$3.49M '25 Q2 25-08-14 · $1,000 −$4.44M '25 Q3 25-11-12 · $ −$3.77M '25 Q4 26-03-23 ▼100% $ −$2.56M '26 Q1 26-05-13 LATEST · $ −$4.31M '26 Q2 26-08-12
Earnings call
FY26 · Q2
2026-08-12
Talphera to Report Second Quarter 2026 Financial Results on Wednesday, August 12, 2026
Revenue
$
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY26 · Q1
2026-05-13
Talphera, Inc. Q1 FY2026 Earnings Call
Confident tone Nafamostat Clinical Advantages vs. Heparin/Citrate NEPHRO Study Enrollment Progress Niyad PMA Approval Pathway
Revenue
$
▼ 100% YoY
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY25 · Q4
2026-03-23
Earnings conference call (announced in 8-K)
Revenue
$*
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-K
Earnings call
FY25 · Q3
2025-11-12
Talphera, Inc. Q3 FY2025 Earnings Call
Positive tone Nephro study enrollment and site activation Financing and capital position Nefamostat product profile and commercial positioning
Revenue
$1,000
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY25 · Q2
2025-08-14
Talphera, Inc. Q2 FY2025 Earnings Call
Confident tone Niyad/nafamostat regulatory and clinical positioning Heparin and citrate shortages / market need Compassionate use IDE
Revenue
$
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY25 · Q1
2025-05-14
Talphera, Inc. Q1 FY2025 Earnings Call
Confident tone NEPHRO CRRT trial progress Compassionate use IDE Niyad commercial opportunity
Revenue
$27,000
Diluted EPS
$-0.10
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY24 · Q4
2025-03-31
Talphera, Inc. Q4 FY2024 Earnings Call
Revenue
$*
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-K
Earnings call
FY24 · Q3
2024-11-13
Talphera, Inc. Q3 FY2024 Earnings Call
Positive tone NEPHRO CRRT registrational trial Trial execution shortfalls and remediation Regulatory pathway and FDA
Revenue
$
▼ 100% YoY
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY24 · Q2
2024-08-14
Talphera, Inc. Q2 FY2024 Earnings Call
Positive tone Leadership transition and new Chief Development Officer NEPHRO study progress and site expansion Financial runway and capital position
Revenue
$
▼ 100% YoY
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY24 · Q1
2024-05-14
Talphera, Inc. Q1 FY2024 Earnings Call
Positive tone Market opportunity and pricing for Niyad Niyad product profile vs. heparin and citrate NEPHRO CRRT study and enrollment
Revenue
$
Diluted EPS
$-0.16
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY23 · Q4
2024-01-22
Talphera, Inc. Q4 FY2023 Earnings Call
Positive tone Niyad registrational study Market opportunity for regional anticoagulant Corporate rebranding and governance
Results not yet reported
Audio Transcript Slides 8-K10-K
Earnings call
FY23 · Q3
2023-11-08
Talphera, Inc. Q3 FY2023 Earnings Call
Revenue
$117,000
Diluted EPS
$-0.08
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY23 · Q2
2023-08-10
Talphera, Inc. Q2 FY2023 Earnings Call
Revenue
$253,000
Diluted EPS
$-0.40
▼ 104.7% YoY
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY23 · Q1
2023-05-10
Talphera, Inc. Q1 FY2023 Earnings Call
Results not yet reported
Audio Transcript Slides 8-K10-Q
Earnings call
FY22 · Q4
2023-03-30
Talphera, Inc. Q4 FY2022 Earnings Call
Revenue
$*
▼ 22200% YoY
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-K
Earnings call
FY22 · Q3
2022-11-14
Talphera, Inc. Q3 FY2022 Earnings Call
Revenue
$
▼ 100% YoY
Diluted EPS
$-0.94
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY22 · Q2
2022-08-11
Talphera, Inc. Q2 FY2022 Earnings Call
Revenue
$
▼ 100% YoY
Diluted EPS
$8.58
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY22 · Q1
2022-05-16
Talphera, Inc. Q1 FY2022 Earnings Call
Revenue
$442,000
▼ 13.5% YoY
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY21 · Q4
2022-03-10
Talphera, Inc. Q4 FY2021 Earnings Call
Revenue
$2,000*
▼ 99.7% YoY
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-K
Earnings call
FY21 · Q3
2021-11-15
Talphera, Inc. Q3 FY2021 Earnings Call
Revenue
$1.86M
▲ 36.1% YoY
Diluted EPS
$-1.40
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY21 · Q2
2021-08-16
Talphera, Inc. Q2 FY2021 Earnings Call
Revenue
$443,000
▼ 84.8% YoY
Diluted EPS
$-1.60
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY21 · Q1
2021-05-17
Talphera, Inc. Q1 FY2021 Earnings Call
Revenue
$511,000
▲ 32.4% YoY
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY20 · Q4
2021-03-15
Talphera, Inc. Q4 FY2020 Earnings Call
Revenue
$738,000*
▲ 55.4% YoY
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-K
Earnings call
FY20 · Q3
2020-11-05
Talphera, Inc. Q3 FY2020 Earnings Call
Revenue
$1.37M
▲ 125% YoY
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY19 · Q4
2020-03-16
Talphera, Inc. Q4 FY2019 Earnings Call
Revenue
$475,000
▼ 22.5% YoY
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-K
Showing 1–25 of 25 earnings calls
Key facts CIK 1427925 CUSIP 00444T209 13F (30d) 50 filings 49 filers Visit website Investor relations

Report a Problem

Category
Description
Email (optional, for follow-up)